|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
0.000 (0.000%) | 2024/06 - Interim RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | (76,646) | (303,266) | (365,778) | (225,313) |
| Net Cash from / (used in) Investing Activities | -- | (100,278) | (153,738) | (84,131) | (188,180) |
| Net Cash from / (used in) Financing Activities | -- | (37,819) | 587,200 | 219,440 | 868,442 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | (214,743) | 130,196 | (230,469) | 454,949 |
| Cash & Cash Equivalents at beginning of period | -- | 610,882 | 466,445 | 697,294 | 246,384 |
| Effect of Foreign Exchange Rate Changes | -- | 3,468 | 14,241 | (380) | (4,039) |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 399,607 | 610,882 | 466,445 | 697,294 |
| Remarks: | Real time quote last updated: 25/11/2024 07:42 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -50,673,000 |
| %Change | -73.303% |
| EPS / (LPS) | RMB -0.130 |
| NBV Per Share (¥) | RMB 1.852 |